Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002025 · ClinicalTrials.gov registry record · NA
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
NCT00002025: Completed NA study, sponsored by Hoffmann-La Roche.
NCT00002025 is a NA study that has completed, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002025, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a controlled clinical study of ganciclovir therapy. To determine the safety and tolerance of 2 - 3 weeks induction course of ganciclovir IV followed by a maintenance course of ganciclovir IV for an indefinite duration. To tabulate the patient's clinical response.
Interventions
- DRUG Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002025 record still lists
NCT00002025 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Ganciclovir is the first listed.
NCT00002025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002025 about?
NCT00002025 is a clinical study titled "Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient". To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a controlled clinical study of ganciclovir therapy. To determine the safety ...
What is the current status of trial NCT00002025?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002025?
The interventions under investigation include: Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00002025?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.